scholarly journals Detection of suPAR in the Saliva of Healthy Young Adults: Comparison with Plasma Levels

2011 ◽  
Vol 6 ◽  
pp. BMI.S8326 ◽  
Author(s):  
Anna Gustafsson ◽  
Vjosa Ajeti ◽  
Lennart Ljunggren
Keyword(s):  
Cardiovascular Disease ◽  
Cerebrospinal Fluid ◽  
Young Adults ◽  
Plasma Levels ◽  
Healthy Individuals ◽  
Urokinase Plasminogen Activator Receptor ◽  
Cystic Fluid ◽  
Whole Saliva ◽  
Plasminogen Activator Receptor ◽  
Unstimulated Whole Saliva

The soluble urokinase plasminogen activator receptor (suPAR) has been detected in blood, plasma, serum, urine, ovarian cystic fluid, and cerebrospinal fluid. Elevated suPAR levels in plasma have been associated with negative outcomes in various diseases, such as bacteremia, sepsis, SIRS, cardiovascular disease, cancer, and tuberculosis. The primary aim of this study was to investigate whether suPAR can be detected in saliva from healthy individuals and thus, if saliva suPAR can be related to plasma suPAR, CRP, BMI, or gender. Blood and unstimulated whole saliva was collected from 20 healthy individuals (10 female and 10 male, median age of 28 years; range 21–41). CRP and suPAR were measured with ELISA in saliva and serum/plasma. suPAR was detected in all saliva samples in the 5.2–28.1 ng/mL range, with a median value of 17.1 ng/mL. Saliva suPAR was significantly higher ( P < 0.001) but not correlated to plasma suPAR in healthy young adults with normal plasma suPAR levels. suPAR and CRP levels were correlated in blood but not in saliva. No correlation was found between BMI, age, or gender and suPAR in saliva.

The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer

Apmis ◽  
1999 ◽  
Vol 107 (1-6) ◽  
pp. 160-167 ◽  
Author(s):  
NILS BRÜNNER ◽  
HANS JØRGEN NIELSEN ◽  
MARIA HAMERS ◽  
IB JARLE CHRISTENSEN ◽  
OLE THORLACIUS-USSING ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Urokinase Plasminogen Activator ◽  
Healthy Individuals ◽  
Urokinase Plasminogen Activator Receptor ◽  
Patients With Cancer ◽  
Plasminogen Activator Receptor

Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer

2017 ◽  
Vol 70 (12) ◽  
pp. 1063-1068
Author(s):  
Gitte Kristensen ◽  
Kasper Drimer Berg ◽  
Solvej Lippert ◽  
Ib Jarle Christensen ◽  
Klaus Brasso ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Plasminogen Activator ◽  
Plasma Levels ◽  
Specific Antigen ◽  
Roc Curves ◽  
Urokinase Plasminogen Activator ◽  
Clinicopathological Parameters ◽  
Prognostic Information ◽  
Urokinase Plasminogen Activator Receptor ◽  
Plasminogen Activator Receptor

AimsLymph node metastasis (N1) is an adverse prognostic factor for men with clinically localised prostate cancer (PCa), but the prediction of N1 disease remains difficult. Urokinase plasminogen activator receptor (uPAR) plays an important role in angiogenesis and tumorigenesis. We analysed whether plasma levels of the soluble uPAR forms uPAR(I-III), uPAR(II-III) and uPAR(I) were associated with the risk of N1 disease in men with clinically localised PCa.MethodsThe present study includes all men (n=518) who underwent radical prostatectomy (RP) for clinically localised PCa, 29 of whom had N1 disease. Soluble uPAR forms were measured using three time-resolved fluorescence immunoassays. The prognostic value of the different uPAR forms together with clinicopathological parameters for N1 disease were analysed using logistic regression, receiver operating characteristic (ROC) regression analysis and quantified using the areas under the ROC curve (AUC).ResultsAll soluble uPAR levels were significantly (p=0.03) higher in patients with N1 disease compared with patients with N0/x disease. ROC curves including clinical tumour stage, biopsy Gleason score, prostate-specific antigen and percent positive biopsies had an AUC of 87.7% for prediction of N1 disease. With the addition of uPAR(I) to the model, the AUC increased to 88.4%.ConclusionsAddition of uPAR(I) level to known diagnostic parameters did not increase the prediction of N1 disease following RP in men with clinically localised PCa. Our results indicate that the plasma levels at diagnosis of the different uPAR forms do not hold important predictive or prognostic information in men with clinically localised PCa.

Soluble Urokinase Plasminogen Activator Receptor: Genetic Variation and Cardiovascular Disease Risk in Blacks

2021 ◽  
Author(s):  
Nels C. Olson ◽  
Laura M. Raffield ◽  
Anne H. Moxley ◽  
Tyne W. Miller-Fleming ◽  
Paul L. Auer ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Genetic Variation ◽  
Plasminogen Activator ◽  
Urokinase Plasminogen Activator ◽  
Cvd Risk Factors ◽  
Cvd Risk ◽  
Urokinase Plasminogen Activator Receptor ◽  
Enhancer Element ◽  
Plasminogen Activator Receptor

Background: suPAR (Soluble urokinase plasminogen activator receptor) has emerged as an important biomarker of coagulation, inflammation, and cardiovascular disease (CVD) risk. The contribution of suPAR to CVD risk and its genetic influence in the Black population have not been evaluated. Methods: We measured suPAR in 3492 Blacks from the prospective, community-based JHS (Jackson Heart Study). Cross-sectional associations of suPAR with lifestyle and CVD risk factors were assessed, whole-genome sequence data were used to evaluate genetic associations of suPAR, and relationships of suPAR with incident CVD outcomes and overall mortality were estimated over follow-up. Results: In Cox models adjusted for traditional CVD risk factors, estimated glomerular filtration rate, and CRP (C-reactive protein), each 1-SD higher suPAR was associated with a 21% to 31% increased risk of incident coronary heart disease, heart failure, stroke, and mortality. In the genome-wide association study, 2 missense (rs399145 encoding p.Thr86Ala, rs4760 encoding p.Phe272Leu) and 2 noncoding regulatory variants (rs73935023 within an enhancer element and rs4251805 within the promoter) of PLAUR on chromosome 19 were each independently associated with suPAR and together explained 14% of suPAR phenotypic variation. The allele frequencies of each of the four suPAR-associated genetic variants differ considerably across African and European populations. We further show that PLAUR rs73935023 can alter transcriptional activity in vitro. We did not find any association between genetically determined suPAR and CVD in JHS or a larger electronic medical record-based analyses of Blacks or Whites. Conclusions: Our results demonstrate the importance of ancestry-differentiated genetic variation on suPAR levels and indicate suPAR is a CVD biomarker in Black adults.

Sign in / Sign up

Export Citation Format

Share Document